Results 211 to 220 of about 921,873 (354)

Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF ...
Albert Aboseif   +17 more
wiley   +1 more source

Moderators and Mediators of Pain and Function Outcomes in a New Service Delivery Model for Management of Knee Osteoarthritis in Primary Care: Secondary Exploratory Analysis of a Randomized Controlled Trial

open access: yesArthritis Care &Research, EarlyView.
Objective Our objective was to explore moderators and mediators influenced changes in pain and function in people with knee osteoarthritis (OA) receiving a new model of primary care service delivery (Optimizing Primary Care Management of Knee Osteoarthritis [PARTNER]), at 12 months (ACTRN: 12617001595303).
Abdolhay Farivar   +12 more
wiley   +1 more source

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

open access: yesArthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy